| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Michael Poyurovsky, Abraham Weizma. Quetiapine in the Treatment of Comorbid Burning Mouth Syndrome and Bipolar II Depression: Case Report. Journal of clinical psychopharmacology. 2024-05-02. PMID:38695727. |
quetiapine in the treatment of comorbid burning mouth syndrome and bipolar ii depression: case report. |
2024-05-02 |
2024-05-04 |
Not clear |
| Taro Kishi, Nakao Iwata, Hiroyuki Irie, Masaru Aikaw. Post-marketing surveillance of quetiapine fumarate extended-release tablets in patients with bipolar depression. Neuropsychopharmacology reports. 2024-04-30. PMID:38686532. |
this study aimed to verify the real-world efficacy and safety of quetiapine fumarate extended-release tablets (bipresso® 50 mg and 150 mg; marketing authorization holder is kyowa pharmaceutical industry co., ltd., osaka, japan) in patients with bipolar depression. |
2024-04-30 |
2024-05-03 |
Not clear |
| Taro Kishi, Nakao Iwata, Hiroyuki Irie, Masaru Aikaw. Post-marketing surveillance of quetiapine fumarate extended-release tablets in patients with bipolar depression. Neuropsychopharmacology reports. 2024-04-30. PMID:38686532. |
post-marketing surveillance of quetiapine fumarate extended-release tablets in patients with bipolar depression. |
2024-04-30 |
2024-05-03 |
Not clear |
| Chuanjun Zhuo, Chao Li, Hongjun Tian, Ranli Li, Feng Jia, Lina Wang, Xiaoyan Ma, Lei Yang, Qiuyu Zhang, Ying Zhang, Kaifang Ya. Molecular mechanisms of quetiapine bidirectional regulation of bipolar depression and mania based on network pharmacology and molecular docking: Evidence from computational biology. Journal of affective disorders. 2024-03-22. PMID:38518857. |
molecular mechanisms of quetiapine bidirectional regulation of bipolar depression and mania based on network pharmacology and molecular docking: evidence from computational biology. |
2024-03-22 |
2024-03-25 |
Not clear |
| Chuanjun Zhuo, Chao Li, Hongjun Tian, Ranli Li, Feng Jia, Lina Wang, Xiaoyan Ma, Lei Yang, Qiuyu Zhang, Ying Zhang, Kaifang Ya. Molecular mechanisms of quetiapine bidirectional regulation of bipolar depression and mania based on network pharmacology and molecular docking: Evidence from computational biology. Journal of affective disorders. 2024-03-22. PMID:38518857. |
quetiapine monotherapy is recommended as the first-line option for acute mania and acute bipolar depression. |
2024-03-22 |
2024-03-25 |
Not clear |
| Chuanjun Zhuo, Chao Li, Hongjun Tian, Ranli Li, Feng Jia, Lina Wang, Xiaoyan Ma, Lei Yang, Qiuyu Zhang, Ying Zhang, Kaifang Ya. Molecular mechanisms of quetiapine bidirectional regulation of bipolar depression and mania based on network pharmacology and molecular docking: Evidence from computational biology. Journal of affective disorders. 2024-03-22. PMID:38518857. |
network pharmacology and molecular docking were employed to determine the molecular mechanisms of quetiapine bidirectional regulation of bipolar depression and mania. |
2024-03-22 |
2024-03-25 |
Not clear |
| Mark H Ebel. Esketamine Is Superior to Quetiapine for Remission of Treatment-Resistant Depression. American family physician. vol 109. issue 2. 2024-02-23. PMID:38393811. |
esketamine is superior to quetiapine for remission of treatment-resistant depression. |
2024-02-23 |
2024-02-26 |
Not clear |
| Yupei Hao, Jinyuan Zhang, Jing Yu, Ze Yu, Lin Yang, Xin Hao, Fei Gao, Chunhua Zho. Predicting quetiapine dose in patients with depression using machine learning techniques based on real-world evidence. Annals of general psychiatry. vol 23. issue 1. 2024-01-06. PMID:38184628. |
predicting quetiapine dose in patients with depression using machine learning techniques based on real-world evidence. |
2024-01-06 |
2024-01-09 |
Not clear |
| Chiao-Hsin Lan, James C-C We. Esketamine Nasal Spray versus Quetiapine for Resistant Depression. The New England journal of medicine. vol 390. issue 1. 2024-01-04. PMID:38169503. |
esketamine nasal spray versus quetiapine for resistant depression. |
2024-01-04 |
2024-01-06 |
Not clear |
| Mark A Horowitz, Martin Plöderl, Florian Naude. Esketamine Nasal Spray versus Quetiapine for Resistant Depression. The New England journal of medicine. vol 390. issue 1. 2024-01-04. PMID:38169502. |
esketamine nasal spray versus quetiapine for resistant depression. |
2024-01-04 |
2024-01-06 |
Not clear |
| Andreas Reif, Siobhán Mulhern-Haughey, Yordan Godino. Esketamine Nasal Spray versus Quetiapine for Resistant Depression. Reply. The New England journal of medicine. vol 390. issue 1. 2024-01-03. PMID:38169504. |
esketamine nasal spray versus quetiapine for resistant depression. |
2024-01-03 |
2024-01-06 |
Not clear |
| Xue-Zhu Feng, Zhe Li, Zi-Yi Li, Ke Wang, Xuan Tan, Yu-Yu Zhao, Wei-Feng Mi, Wei-Li Zhu, Yan-Ping Bao, Lin Lu, Su-Xia L. Effectiveness and safety of second-generation antipsychotics for psychiatric disorders apart from schizophrenia: A systematic review and meta-analysis. Psychiatry research. vol 332. 2023-12-27. PMID:38150810. |
aripiprazole is the most effective treatment for bipolar mania [effect size = -0.90, 95% ci: -1.59, -0.21] and tourette's disorder [effect size = -0.80, 95% ci: -1.14, -0.45], olanzapine for bipolar depression [effect size = -0.86, 95% ci: -1.32, -0.39] and post-traumatic stress disorder [effect size = -0.98, 95% ci: -1.55, -0.41], lurasidone for depression [effect size = -0.66, 95% ci: -0.82, -0.50], quetiapine for anxiety [effect size = -1.20, 95% ci: -1.96, -0.43], sleep disorders [effect size = -1.2, 95% ci: -1.97, -0.58], and delirium [effect size = -0.36, 95% ci: -0.70, -0.03], and risperidone for obsessive-compulsive disorder [effect size = -2.37, 95% ci: -3.25, -1.49], respectively. |
2023-12-27 |
2023-12-30 |
Not clear |
| Christophe Moderie, Jacob D King, Nicolas Nuñez, Stefano Comai, Gabriella Gobb. Sleep Quality After Quetiapine Augmentation in Patients With Treatment-Resistant Depression and Personality Disorders. Journal of clinical psychopharmacology. vol 43. issue 6. 2023-11-06. PMID:37930201. |
sleep quality after quetiapine augmentation in patients with treatment-resistant depression and personality disorders. |
2023-11-06 |
2023-11-08 |
Not clear |
| Christophe Moderie, Jacob D King, Nicolas Nuñez, Stefano Comai, Gabriella Gobb. Sleep Quality After Quetiapine Augmentation in Patients With Treatment-Resistant Depression and Personality Disorders. Journal of clinical psychopharmacology. vol 43. issue 6. 2023-11-06. PMID:37930201. |
quetiapine is a first-line augmenting agent for treatment-resistant depression (trd) and is used off-label in insomnia. |
2023-11-06 |
2023-11-08 |
Not clear |
| Emily Harri. Esketamine More Effective Than Quetiapine for Hard-to-Treat Depression. JAMA. 2023-10-18. PMID:37851473. |
esketamine more effective than quetiapine for hard-to-treat depression. |
2023-10-18 |
2023-11-08 |
Not clear |
| Andreas Reif, Istvan Bitter, Jozefien Buyze, Kerstin Cebulla, Richard Frey, Dong-Jing Fu, Tetsuro Ito, Yerkebulan Kambarov, Pierre-Michel Llorca, Albino J Oliveira-Maia, Thomas Messer, Siobhán Mulhern-Haughey, Benoît Rive, Christian von Holt, Allan H Young, Yordan Godino. Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. The New England journal of medicine. vol 389. issue 14. 2023-10-04. PMID:37792613. |
esketamine nasal spray versus quetiapine for treatment-resistant depression. |
2023-10-04 |
2023-10-07 |
Not clear |
| Andreas Reif, Istvan Bitter, Jozefien Buyze, Kerstin Cebulla, Richard Frey, Dong-Jing Fu, Tetsuro Ito, Yerkebulan Kambarov, Pierre-Michel Llorca, Albino J Oliveira-Maia, Thomas Messer, Siobhán Mulhern-Haughey, Benoît Rive, Christian von Holt, Allan H Young, Yordan Godino. Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. The New England journal of medicine. vol 389. issue 14. 2023-10-04. PMID:37792613. |
the efficacy and safety of esketamine nasal spray as compared with extended-release quetiapine augmentation therapy, both in combination with ongoing treatment with a selective serotonin reuptake inhibitor (ssri) or a serotonin-norepinephrine reuptake inhibitor (snri), in patients with treatment-resistant depression are unknown. |
2023-10-04 |
2023-10-07 |
Not clear |
| Lin Yang, Jinyuan Zhang, Jing Yu, Ze Yu, Xin Hao, Fei Gao, Chunhua Zho. Predicting plasma concentration of quetiapine in patients with depression using machine learning techniques based on real-world evidence. Expert review of clinical pharmacology. 2023-07-19. PMID:37466101. |
predicting plasma concentration of quetiapine in patients with depression using machine learning techniques based on real-world evidence. |
2023-07-19 |
2023-08-14 |
Not clear |
| Hossein Navay Baghban, Kambiz Ghaseminasab, Mohammad Hasanzade. Construction of a hydrophobic-hydrophilic open-droplet microfluidic chemosensor towards colorimetric/spectrophotometric recognition of quetiapine fumarate: a cost-benefit method for biomedical analysis using a smartphone. Analytical methods : advancing methods and applications. 2023-07-14. PMID:37449384. |
quetiapine fumarate (qf) is used to treat a number of mental/emotional diseases, including schizophrenia, bipolar disorder, and abrupt bouts of mania or depression linked to bipolar disorder. |
2023-07-14 |
2023-08-14 |
Not clear |
| Lingzhuo Kong, Yuting Shen, Shaohua Hu, Jianbo La. The impact of quetiapine monotherapy or in combination with lithium on the thyroid function in patients with bipolar depression: A retrospective study. CNS neuroscience & therapeutics. 2023-07-10. PMID:37424160. |
the impact of quetiapine monotherapy or in combination with lithium on the thyroid function in patients with bipolar depression: a retrospective study. |
2023-07-10 |
2023-08-14 |
Not clear |